On September 12, 2017 BioInvent International AB (OMXS: BINV) reported that the Japanese patent office has decided that the company’s first patent application relating to the immune-oncology antibody BI-1206 now can proceed to grant (Press release, BioInvent, SEP 12, 2017, View Source [SID1234520495]). The patent will be granted once all remaining administrative actions, such as payment of fees, have been completed by BioInvent. This patent is important since it covers the use of the company’s drug candidate BI-1206, and similarCD32b antibodies, in combination with a CD19 or CD20 antibody, such as rituximab, in the treatment of cancer or inflammatory diseases in certain groups of patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This will be the third patent granted in this patent family, after the patents granted in Australia and by the European Patent Office. There are also corresponding patent applications pending in other countries.